Risks
4 risks
Risk Intelligence
Geopolitical instability impacting global business
View Risks →Alivus Life Sciences Limited — Q3 FY26
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crore, up 4.8% YoY, driven by a strong CDMO recovery (85.3% YoY growth) and robust non-GPL business growth of 16.1%.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crore, up 4.8% YoY, driven by a strong CDMO recovery (85.3% YoY growth) and robust non-GPL business growth of 16.1%. EBITDA margin expanded 510 bps YoY to 36.4%, the highest ever, supported by new product launches, favorable mix, and operational efficiencies. Management raised margin guidance to 30-32% (from 28-30%) and expects high single-digit revenue growth for FY26. Capex guidance was reduced to ₹450 crore (from ₹600 crore), with ₹150 crore deferred to FY27. Key risks include geopolitical instability and pricing erosion in mature molecules, though management sees these as manageable. The CDMO pipeline remains strong with 5 active projects and potential for 2 more by Q1 FY27.
एलिवस लाइफ साइंसेज ने अपनी अब तक की सबसे बड़ी तिमाही कमाई ₹673 करोड़ दर्ज की, जो पिछले साल से 4.8% अधिक है। यह वृद्धि मुख्य रूप से CDMO (दवा बनाने की सेवा) में 85.3% की जबरदस्त बढ़ोतरी और गैर-GPL (सामान्य दवाओं के अलावा) कारोबार में 16.1% वृद्धि से हुई। कंपनी का मुनाफा मार्जिन (EBITDA) 36.4% तक पहुंच गया, जो पिछले साल से 5.1% अधिक है। यह नई दवाओं, बेहतर उत्पाद मिश्रण और कुशल संचालन से संभव हुआ। प्रबंधन ने अब मार्जिन 30-32% रहने का अनुमान लगाया है और अगले वित्त वर्ष में कमाई में एकल अंकों की वृद्धि की उम्मीद है। पूंजी खर्च ₹600 करोड़ से घटाकर ₹450 करोड़ किया गया। जोखिमों में भू-राजनीतिक अस्थिरता और पुरानी दवाओं की कीमतों में गिरावट शामिल है, लेकिन प्रबंधन इसे संभालने योग्य मानता है। CDMO में 5 सक्रिय परियोजनाएं हैं और अगले साल तक 2 और जुड़ सकती हैं।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
CDMO Revenue Growth
85.3%
+85.3% YoY
CDMO segment revenue grew 85.3% YoY in Q3, driven by new projects and strong recovery.
Gross Margin
58.9%
+330 bps YoY
Gross margin expanded 330 bps YoY to 58.9% due to product mix and efficiency gains.
DMF/CMF Filings
595
N/A
Global DMF and CMF filings stood at 595 as of Dec 31, 2025, supporting future launches.
High Potent API Pipeline
27 products
N/A
27 high potent API products in active pipeline, targeting $70B addressable market.
What Changed vs Last Quarter
NEW
EBITDA margin guidance raised to 30-32%
EBITDA margin expected to be in 30-32% range going forward, up from earlier guidance of 28-30%.
NEW
CDMO: 1-2 new projects expected by Q1 FY27
Management expects to conclude 1-2 new CDMO projects by Q1 FY27, with early quantities already supplied.
UPDATED
Revenue growth: high single-digit for FY26
Management expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.
UPDATED
Capex guidance reduced to ₹450 crore for FY26
Capex for FY26 now guided at ₹450 crore, down from ₹600 crore, with ₹150 crore deferred to FY27.
DROPPED
Sustain EBITDA margins around 30%
Management expects to sustain EBITDA margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiency.
DROPPED
CDMO turnaround in H2 FY26
Management expects a meaningful turnaround in CDMO performance in H2, driven by new project additions and ramp-up of existing projects.
NEW RISK
Geopolitical instability impacting global business
Management highlighted geopolitical risks as a key concern given the company's international presence, though diversification mitigates impact.
NEW RISK
CDMO growth slower than peers due to smaller deal sizes
Analyst questioned why CDMO deal sizes are limited to $4-6M vs peers targeting $50-100M; management defended strategy citing high attrition and tax-driven manufacturing in Ireland.
NEW RISK
Pricing erosion in mature molecules
Management acknowledged 4-4.5% annual price erosion across the portfolio, but expects to offset via next-gen processes and new launches.
NEW RISK
Sholapur capacity delay and scale-down
Sholapur plant delayed by ~3 months to July 2026, and initial capacity reduced from 600kL to 450-500kL, though management says it won't impact growth.
RISK GONE
CDMO turnaround may be delayed
CDMO performance remained soft in Q2; management expects rebound in H2 but any delay in project ramp-ups or regulatory approvals could impact growth.
RISK GONE
GPL recovery uncertain
GPL segment declined due to customer inventory rationalization; management expects recovery in H2 but could not quantify, leaving uncertainty.
RISK GONE
Capex delays may constrain future growth
Capex spend has been slower than planned; while management says it won't impact near-term growth, delays in capacity expansion could limit medium-term scalability.
RISK GONE
Regulatory compliance incident at Gujarat plant
A flash fire led to a penalty from the Gujarat State Pollution Control Board; while management downplays it, repeated issues could affect operations.
Fast read
Guidance and risk preview
Management expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.
Management highlighted geopolitical risks as a key concern given the company's international presence, though diversification mitigates impact.
View Risks →